Class information for:
Level 1: PD L1//PD 1//IPILIMUMAB

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
721 3134 47.0 90%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
10 3       IMMUNOLOGY//JOURNAL OF IMMUNOLOGY//IMMUNOL 134299
919 2             PD L1//PD 1//FOXP3 11160
721 1                   PD L1//PD 1//IPILIMUMAB 3134

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 PD L1 authKW 2661149 12% 72% 378
2 PD 1 authKW 2196088 13% 57% 393
3 IPILIMUMAB authKW 1624998 9% 61% 274
4 NIVOLUMAB authKW 1344388 6% 76% 182
5 PEMBROLIZUMAB authKW 892311 4% 78% 118
6 PROGRAMMED DEATH 1 authKW 534951 3% 62% 88
7 IMMUNE CHECKPOINT authKW 430105 3% 53% 83
8 B7 H1 authKW 418349 3% 54% 80
9 PD L2 authKW 417712 2% 79% 54
10 IMMUNE CHECKPOINT INHIBITORS authKW 405499 2% 57% 73

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Oncology 26820 48% 0% 1501
2 Immunology 11754 30% 0% 944
3 Medicine, Research & Experimental 1920 10% 0% 321
4 Hematology 279 4% 0% 116
5 Cell Biology 268 7% 0% 214
6 Dermatology 201 2% 0% 77
7 Pathology 172 3% 0% 88
8 Respiratory System 150 2% 0% 76
9 Rheumatology 77 1% 0% 38
10 Biotechnology & Applied Microbiology 43 3% 0% 99

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 LUDWIG CANC IMMUNOTHER Y 217387 2% 45% 50
2 MED ONCOL IMMUNOTHER Y 67773 1% 30% 23
3 DONALD A ADAM COMPREHENS MELANOMA 56119 0% 52% 11
4 MELANOMA DIS 40632 0% 38% 11
5 DERMOPATH 38966 0% 100% 4
6 IMMUNOONCOL 36535 1% 22% 17
7 MELANOMA IMMUNOTHER EUT SERV 34627 0% 44% 8
8 CANC PRECIS MED 31876 0% 55% 6
9 MED ONCOL 30915 12% 1% 386
10 DERMATOLCICU976 29224 0% 100% 3

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CANCER IMMUNOLOGY RESEARCH 156614 3% 19% 85
2 ONCOIMMUNOLOGY 42976 2% 7% 65
3 IMMUNOTHERAPY 18452 1% 5% 37
4 JOURNAL OF IMMUNOTHERAPY 12180 1% 3% 46
5 CLINICAL CANCER RESEARCH 8835 4% 1% 117
6 PROGRESS IN TUMOR RESEARCH 8653 0% 22% 4
7 ONCOLOGY RESEARCH AND TREATMENT 5611 0% 5% 12
8 JAMA ONCOLOGY 5218 0% 5% 11
9 ONCOTARGET 4837 3% 1% 79
10 MELANOMA RESEARCH 4614 1% 2% 29

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 PD L1 2661149 12% 72% 378 Search PD+L1 Search PD+L1
2 PD 1 2196088 13% 57% 393 Search PD+1 Search PD+1
3 IPILIMUMAB 1624998 9% 61% 274 Search IPILIMUMAB Search IPILIMUMAB
4 NIVOLUMAB 1344388 6% 76% 182 Search NIVOLUMAB Search NIVOLUMAB
5 PEMBROLIZUMAB 892311 4% 78% 118 Search PEMBROLIZUMAB Search PEMBROLIZUMAB
6 PROGRAMMED DEATH 1 534951 3% 62% 88 Search PROGRAMMED+DEATH+1 Search PROGRAMMED+DEATH+1
7 IMMUNE CHECKPOINT 430105 3% 53% 83 Search IMMUNE+CHECKPOINT Search IMMUNE+CHECKPOINT
8 B7 H1 418349 3% 54% 80 Search B7+H1 Search B7+H1
9 PD L2 417712 2% 79% 54 Search PD+L2 Search PD+L2
10 IMMUNE CHECKPOINT INHIBITORS 405499 2% 57% 73 Search IMMUNE+CHECKPOINT+INHIBITORS Search IMMUNE+CHECKPOINT+INHIBITORS

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 KEIR, ME , BUTTE, MJ , FREEMAN, GJ , SHARPEL, AH , (2008) PD-1 AND ITS LIGANDS IN TOLERANCE AND IMMUNITY.ANNUAL REVIEW OF IMMUNOLOGY. VOL. 26. ISSUE . P. 677 -704 113 76% 1242
2 POSTOW, MA , CALLAHAN, MK , WOLCHOK, JD , (2015) IMMUNE CHECKPOINT BLOCKADE IN CANCER THERAPY.JOURNAL OF CLINICAL ONCOLOGY. VOL. 33. ISSUE 17. P. 1974 -U161 67 82% 225
3 SPAIN, L , DIEM, S , LARKIN, J , (2016) MANAGEMENT OF TOXICITIES OF IMMUNE CHECKPOINT INHIBITORS.CANCER TREATMENT REVIEWS. VOL. 44. ISSUE . P. 51 -60 60 97% 25
4 PARDOLL, DM , (2012) THE BLOCKADE OF IMMUNE CHECKPOINTS IN CANCER IMMUNOTHERAPY.NATURE REVIEWS CANCER. VOL. 12. ISSUE 4. P. 252 -264 64 54% 1583
5 ZOU, WP , WOLCHOK, JD , CHEN, LP , (2016) PD-L1 (B7-H1) AND PD-1 PATHWAY BLOCKADE FOR CANCER THERAPY: MECHANISMS, RESPONSE BIOMARKERS, AND COMBINATIONS.SCIENCE TRANSLATIONAL MEDICINE. VOL. 8. ISSUE 328. P. - 92 53% 33
6 TOPALIAN, SL , TAUBE, JM , ANDERS, RA , PARDOLL, DM , (2016) MECHANISM-DRIVEN BIOMARKERS TO GUIDE IMMUNE CHECKPOINT BLOCKADE IN CANCER THERAPY.NATURE REVIEWS CANCER. VOL. 16. ISSUE 5. P. 275 -287 73 63% 35
7 BERTRAND, A , KOSTINE, M , BARNETCHE, T , TRUCHETET, ME , SCHAEVERBEKE, T , (2015) IMMUNE RELATED ADVERSE EVENTS ASSOCIATED WITH ANTI-CTLA-4 ANTIBODIES: SYSTEMATIC REVIEW AND META-ANALYSIS.BMC MEDICINE. VOL. 13. ISSUE . P. - 91 88% 31
8 BRAHMER, JR , TYKODI, SS , CHOW, LQM , HWU, WJ , TOPALIAN, SL , HWU, P , DRAKE, CG , CAMACHO, LH , KAUH, J , ODUNSI, K , ET AL (2012) SAFETY AND ACTIVITY OF ANTI-PD-L1 ANTIBODY IN PATIENTS WITH ADVANCED CANCER.NEW ENGLAND JOURNAL OF MEDICINE. VOL. 366. ISSUE 26. P. 2455-2465 32 86% 1933
9 TOPALIAN, SL , DRAKE, CG , PARDOLL, DM , (2015) IMMUNE CHECKPOINT BLOCKADE: A COMMON DENOMINATOR APPROACH TO CANCER THERAPY.CANCER CELL. VOL. 27. ISSUE 4. P. 450 -461 60 56% 250
10 SZNOL, M , CHEN, LP , (2013) ANTAGONIST ANTIBODIES TO PD-1 AND B7-H1 (PD-L1) IN THE TREATMENT OF ADVANCED HUMAN CANCER.CLINICAL CANCER RESEARCH. VOL. 19. ISSUE 5. P. 1021-1034 75 86% 148

Classes with closest relation at Level 1


Rank Class id link
1 35492 LAG 3//LYMPHOCYTE ACTIVATION GENE 3//CD223
2 23216 B7 H4//B7 H3//SOLUBLE B7 H4
3 13573 IMMUNOGENIC CELL DEATH//U1015//U805
4 24008 ICOS//B7RP 1//INDUCIBLE COSTIMULATOR
5 4080 REGULATORY T CELLS//FOXP3//TUMOR INFILTRATING LYMPHOCYTES
6 25112 GV1001//PA MSHA VACCINE//HTERTC27
7 16595 TIM 3//GALECTIN 9//TIM 1
8 13629 TUMOR IMMUNOL BIOL//SIPULEUCEL T//5T4
9 2395 CD28//COSTIMULATION//B7
10 1284 VEMURAFENIB//BRAF INHIBITOR//BRAF

Go to start page